Genital Herpes

Genital Herpes

  

What problems can occur to people with Herpes simplex?

Home
Blog - What's New?
Abortion
Acne
Amenorrhoea - Absent Periods
Anatomy Female
Birth Control
Bladder Symptoms
Breast Feeding
Cancer in Women
Childbirth
Diet / Weight Loss
Dysmenorrhoea
Ectopic Pregnancy
Endometrial Ablation
Endometriosis
Female Sexual Problems
Female Sterilization
Fibroids
Urinary Tract Infection - UTI
HRT/HormoneReplacementTherapy
Hysterectomy
Infection
Infertility
Irritable Bowel Syndrome IBS
Libido - Sex Drive
Medication - Drugs
Menopause
Menorrhagia Heavy Periods
Menstruation Menstrual Cycle
Miscarriage
Obesity
Ovarian Cysts
Painful Sex - Dyspareunia
Pap Smear Test
PCOS
Pelvic Inflammatory Disease
Pelvic Pain
PMS- Premenstrual Syndrome
Pregnancy & Childbirth
Prolapse
SHOP / SHOPPING MALL UK
SHOP / Shopping Mall - USA
Ultrasound
Urinary Tract Infection - UTI
Urinary Incontinence
Vaginal Discharge
Viagra, Libido and Sex Drive.
Weight Loss-Dieting
Illustrations
The Author
Contact Us


Obstet Gynecol. 2006 Jul;108(1):141-7.

Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Sheffield JS , Hill JB , Hollier LM , Laibl VR , Roberts SW , Sanchez PJ ,

Wendel GD Jr .

Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9032, USA .Jeanne.Sheffield@utsouthwestern.edu

Objectives:

To measure the efficacy of valacyclovir suppression in late pregnancy to reduce the incidence of recurrent genital herpes in labor and subsequent cesarean delivery.

Methods:

A total of 350 pregnant women with a history of genital herpes were assigned randomly to oral valacyclovir 500 mg twice a day or an identical placebo from 36 weeks of gestation until delivery. In labor, vulvovaginal herpes simplex virus (HSV) culture and polymerase chain reaction (PCR) specimens were collected. Vaginal delivery was permitted if no clinical recurrence or prodromal symptoms were present. Neonatal HSV cultures and laboratory tests were obtained, and infants were followed up for 1 month after delivery. Data were analyzed using chi2 and Student t tests.

Results:

One hundred seventy women treated with valacyclovir and 168 women treated with placebo were evaluated. Eighty-two percent of the women had recurrent genital herpes; 12% had first episode, nonprimary genital herpes; and 6% had first episode, primary genital herpes. At delivery, 28 women (8%) had recurrent genital herpes requiring cesarean delivery: 4% in the valacyclovir group and 13% in the placebo group (P = .009). Herpes simplex virus was detected by culture in 2% of the valacyclovir group and 9% [corrected] of the placebo group (P =.02). No infants were diagnosed with neonatal HSV, and there were no significant differences in neonatal complications. There were no significant differences in maternal or obstetric complications in either group.

Conclusion:

Valacyclovir suppression after 36 weeks of gestation significantly reduces HSV shedding and recurrent genital herpes requiring cesarean delivery.


Back Home Up Next


Please click on the required question.